Ferguson Enterprises Inc. Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Ferguson Enterprises Inc. Common Stock trades at $222 (market cap $43.13B), while State Street SPDR S&P Biotech ETF trades at $147.19 (market cap $10.05B). The key difference: Ferguson Enterprises Inc. Common Stock is far larger — about 4.3× State Street SPDR S&P Biotech ETF's market cap, and Ferguson Enterprises Inc. Common Stock pays a 1.6% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ferguson Enterprises Inc. Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 39 Days on average.
| FERG | XBI | |
|---|---|---|
Market Cap | $43.13B | $10.05B |
Volume | 1,358,634 | 10,367,649 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $267.71 | $169.55 |
52-Week Low | $214.26 | $107.32 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $49.58B | — |
Dividend Yield | 1.6% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $146.8, down 3.04% today amid a bearish technical signal. The ETF's modified equal-weight structure provides exposure to over 150 biotech names, benefiting from M&A activity and positive clinical catalysts. Recent news highlights a 76% prior-year rally and optimism around cancer vaccine breakthroughs from Merck and Moderna. However, the ETF carries higher volatility and expense ratios compared to broader healthcare funds.
Outlook remains mixed with technical indicators bearish but fundamental catalysts present. Investment opportunity lies in targeted biotech exposure and sector innovation, though risks include high volatility, regulatory uncertainty, and reliance on clinical trial successes. Analyst consensus is neutral with 100% hold rating, suggesting cautious optimism amid recent price declines.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Ferguson Enterprises, Inc. distributes plumbing, HVAC, waterworks, and related building products to professional contractors, builders, and facility managers across North America, operating through branches, showrooms, and digital commerce.
Read more on FERG →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →